Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE KIROMIC BIOPHARMA, INC. SECURITIES LITIGATION
Case Number:
1:22-cv-06690
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
October 02, 2023
Drug Co. Investors Settle Clinical Trial Suit For $2.3M
Investors of biotherapeutics company Kiromic BioPharma Inc. asked a New York federal judge to initially approve a $2.3 million settlement in a suit accusing the company of touting prospects for two drug candidates ahead of a 2021 public offering despite knowing the U.S. Food and Drug Administration suspended the drugs' clinical trials.
-
August 08, 2022
Biopharma Co. Accused Of Lying To Investors About FDA Hold
An investor in biotherapeutics company Kiromic BioPharma Inc. has launched a proposed class action accusing the company and its leadership of touting prospects for two drug candidates ahead of a 2021 public offering despite the fact that the U.S. Food and Drug Administration had hit pause on clinical trials for both therapeutics.